COMMUNIQUÉS West-GlobeNewswire

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
25/03/2026
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of [...]
Cellbricks Therapeutics Raises €10 Million New Capital to Move Living Tissue Implants Toward the Clinic
25/03/2026
Funding will accelerate preclinical validation of biofabricated tissue implants for soft tissue repair, wound healing and trauma care - while building the biological and manufacturing foundations for 3D-bioprinted [...]
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
25/03/2026
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8: [...]
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
25/03/2026
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval
25/03/2026
Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes MINNEAPOLIS, March 25, 2026 (GLOBE [...]
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue
25/03/2026
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One [...]
Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers
25/03/2026
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging Clinics TM as [...]
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
25/03/2026
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious [...]
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
25/03/2026
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
ADMA Biologics Addresses Misleading Short-Seller Report
25/03/2026
RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to [...]
Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman
25/03/2026
Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot will be proposed as new members of the [...]
Zelluna ASA [ZLNA]: Annual Report 2025
25/03/2026
Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of [...]
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
25/03/2026
Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments [...]
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
25/03/2026
DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free [...]
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
25/03/2026
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 [...]
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
25/03/2026
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
24/03/2026
Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports [...]
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal [...]
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]

Pages